Complement control for COVID-19

See allHide authors and affiliations

Science Immunology  25 May 2021:
Vol. 6, Issue 59, eabj1014
DOI: 10.1126/sciimmunol.abj1014


Excessive complement activation contributes to lung disease and adverse patient outcomes in COVID-19 (see the related Research Articles by Yan et al. and Ma et al.).

View Full Text

Stay Connected to Science Immunology